
Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.
Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong free cash flow of $10.6 billion over nine months and a conservative payout ratio below 30%. The company maintains a dominant position in HIV therapies w...


